0001415889-23-011447.txt : 20230724 0001415889-23-011447.hdr.sgml : 20230724 20230724194508 ACCESSION NUMBER: 0001415889-23-011447 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230721 FILED AS OF DATE: 20230724 DATE AS OF CHANGE: 20230724 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pontes Josias CENTRAL INDEX KEY: 0001868415 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 231106164 MAIL ADDRESS: STREET 1: C/O SIGILON THERAPEUTICS, INC. STREET 2: 100 BINNEY STREET, SUITE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 form4-07242023_110705.xml X0508 4 2023-07-21 0001821323 Sigilon Therapeutics, Inc. SGTX 0001868415 Pontes Josias C/O SIGILON THERAPEUTICS, INC. 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2023-07-21 4 M 0 1444 19.24 A 3254 D Stock Option (Right to Buy) 19.24 2023-07-21 4 M 0 1444 0 D 2032-02-17 Common Stock 1444 3171 D Includes 786 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase periods from October 1, 2021 to March 31, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. These transaction are exempt under Rule 16b-3(c). Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested. /s/ Matthew Kowalsky, Attorney-in-Fact 2023-07-24